Custom Search

News

Monday 23 July 2007

Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.

By: Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.

Antimicrob Agents Chemother 2007 Aug;51(8):2982-4

Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.

Use of this site is subject to the following terms of use